Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial

• Egile Nagusiak: Zhichao Tian (Egilea), Shuping Dong (Egilea), Wenli Zuo (Egilea), Po Li (Egilea), Fan Zhang (Egilea), Shilei Gao (Egilea), Yonghao Yang (Egilea), Chao Li (Egilea), Peng Zhang (Egilea), Xin Wang (Egilea), Jiaqiang Wang (Egilea), Weitao Yao (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Chemoimmunotherapy is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effect of this combination treatment in patients with metastatic soft tissue sarcoma (STS) are currently limited. This study evaluated the safety and efficacy o...